Abstract: The present disclosure is directed to methods of genetically detecting or generating a peanut line that is resistant to peanut smut infection. The disclosure also relates to cultivation of smut resistant peanut lines and the cessation or prevention of peanut smut in a given geographic area.

Abstract: The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts.

Abstract: The present disclosure is directed to methods for verifying the genetic makeup of a target product, for example, products in a supply chain. The methods relate to the use of genomics for confirming or verifying the genetic makeup of the target product. The methods also relate to the use of genomics for detecting the presence or absence of one or more gene variants associated with a specific phenotypic quality or characteristic in the target product. The presently disclosed method verifies and/or detects certain genetic markers of the target product using whole genome sequencing (WGS) to access the entire genome.

Abstract: A method of reducing the abundance of a non-target micro-RNA (miRNA) that is part of a group of miRNAs is provided, including: (a) annealing a complementary region of a blocking nucleic acid to a binding site at a first end of the unwanted miRNA, ligating an adenylated nucleic acid adapter to the group of miRNAs, and performing RT-PCR on group of miRNAs. Kits and compounds for use with the method are also provided.

Abstract: The present disclosure provides for and relates to the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurrence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth.

Abstract: The present disclosure provides for and relates to cancer treatment based on the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurrence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth.

Abstract: The present disclosure provides for and relates to the identification of novel biomarkers for diagnosis and prognosis of prostate cancer or the biochemical reoccurrence of prostate cancer. The biomarkers of the invention show altered methylation levels of certain CpG loci relative to normal prostate tissue, as set forth.

Abstract: A blocking nucleic acid for use in reducing the abundance of a non-target micro-RNA (miRNA) in an miRNA library is provided, including: a single-stranded complementary region at one of the 5? end of the blocking nucleic acid or the 3? end of the blocking nucleic acid, that anneals with a binding region at a first end of the unwanted miRNA; a hairpin loop forming region or other double-stranded region adjacent to the complimentary region, in which all of the terminal ends of the blocking nucleic acid except one are unavailable to participate in ligase reactions. Methods and kits for using the blocking nucleic acid are also provided.

Abstract: Disclosed is a method for amplifying and detecting polynucleotides which can provide sensitive, specific detection of multiple targets from a clinical specimen within a relatively short time.